Clinical Trial Update: Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers [Phase 2]

View source ↗

Summary

Phase 2 study of nivolumab in patients with advanced refractory biliary tract cancers has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Biliary Tract Neoplasms

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-03-30